<DOC>
	<DOCNO>NCT01371994</DOCNO>
	<brief_summary>The purpose study assess efficacy safety 12 week treatment solifenacin succinate versus placebo participant incontinent Robotic Assisted Radical Prostatectomy . This study also assess effect 12 week treatment solifenacin succinate versus placebo quality life ( QOL ) measure questionnaire .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety With Solifenacin Succinate Improve Urinary Continence After Robotic Assisted Radical Prostatectomy</brief_title>
	<detailed_description>The study duration include 14-day treatment free wash-out period . The maximum total study duration 15 week ( 2-3 week screening/washout period 12 week treatment period ) . The Baseline , Week 4 , Week 8 visit telephone contact visit . Participants complete electronic daily pad use diary study duration . Participants also ask complete several questionnaire study .</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Ambulatory Willing able complete daily pad use diary , American Urology Association Symptom Score ( AUASS ) Bother Score , International Consultation Incontinence Questionnaire Short Form ( ICIQSF ) , Work Productivity Activity Impairment Questionnaire ( WPAI ) Has use medication overactive bladder symptom least 14 day prior enrollment Diagnosed prostate cancer , treat Robotic Assisted Radical Prostatectomy , void spontaneously urinary incontinence one week removal indwell catheter require management 2 10 pad inclusive per day ( 24 hour day ) 7 consecutive day Evidence severe neurologic damage postprostatectomy Evidence chronic urologic inflammation interstitial cystitis bladder stone ; uncontrolled narrow angle glaucoma ; urinary gastric retention neurogenic bladder Symptomatic urinary tract infection urine culture result require treatment determined investigator . Clinically significant history hepatic renal impairment ( 2 X Upper Limit Normal ( ULN ) value alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) creatinine clearance &lt; 30 ml/min ) History diagnose gastrointestinal obstruction disease Any prior history local radiation therapy prostate rectum prior hormonal therapy plan therapy study conduct Known suspect hypersensitivity solifenacin succinate , component , anticholinergic Treated investigational drug within last 30 day History clinically significant illness medical condition would preclude participation study Diagnosed New York Heart Association Class III IV heart failure Any follow perioperative laboratory result : ALT &gt; 2.0 ULN , AST &gt; 2.0 ULN , serum creatinine &gt; 1.5 mg/L , blood glucose &gt; 130 mg/dL , blood urea nitrogen ( BUN ) &gt; 23 mg/dL . Severe hypertension perioperative evaluation define sit systolic blood pressure &gt; 180 mmHg and/or diastolic blood pressure &gt; 110 mmHg , correct Electrolytes ( sodium , potassium , chloride bicarbonate ) normal range clinically significant determine investigator perioperative period . Can eligible electrolyte correct within normal range prior randomization Participated interventional clinical study treat investigational drug within 30 day 5 half life , whichever longer , prior initiation Screening .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Radical Robotic Arm</keyword>
	<keyword>Post Prostatectomy Incontinence</keyword>
	<keyword>Vesicare</keyword>
	<keyword>YM905</keyword>
</DOC>